AI-Driven Early Warning System for Perioperative Risks in Acute Hemorrhagic Stroke
A Large Language Model-Driven Multimodal Early Warning Platform for Perioperative Complications in Acute Hemorrhagic Cerebrovascular Disease
1 other identifier
observational
1,533
1 country
1
Brief Summary
Acute hemorrhagic cerebrovascular disease is a life-threatening condition characterized by sudden onset, rapid progression, multiple complications, poor prognosis, and high mortality. It presents a significant public health burden. During surgical interventions, precise risk stratification and effective perioperative management are crucial to mitigating intraoperative and postoperative complications, optimizing disease diagnosis, guiding severity assessment, and refining anesthesia strategies. Continuous real-time evaluation and dynamic perioperative adjustments are essential to minimize the influence of institutional variability and individual clinician-dependent decision-making. By harnessing big data-driven, evidence-based medical approaches, clinicians can enhance diagnostic accuracy and therapeutic precision, addressing a critical challenge in reducing morbidity and mortality in this patient population. This study aims to develop a comprehensive multimodal perioperative database and leverage large language models (LLMs) for the efficient extraction of structured demographic and clinical data throughout the perioperative course. By integrating real-time hemodynamic monitoring parameters, the investigators seek to elucidate the relationship between perioperative hemodynamic patterns and the incidence of postoperative complications affecting major organ systems, including the brain, heart, kidneys, and lungs. The ultimate goal is to construct a multimodal fusion early-warning model capable of real-time, simultaneous prediction of multiple perioperative complications. This AI-driven platform will function as a risk stratification and alert system for organ-specific perioperative complications in patients with acute hemorrhagic cerebrovascular disease. By providing evidence-based insights for optimized perioperative management-encompassing early warning mechanisms, diagnostic support, and individualized therapeutic strategies-the system aims to improve clinical outcomes, reduce perioperative morbidity, and lower overall mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 9, 2025
CompletedFirst Posted
Study publicly available on registry
May 31, 2025
CompletedStudy Start
First participant enrolled
July 6, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
May 31, 2025
April 1, 2025
2.5 years
May 9, 2025
May 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary outcome measures were postoperative complications involving the neurological, cardiac, pulmonary, and renal systems in patients with acute hemorrhagic cerebrovascular disease following surgical interventions.
Within 30 days after surgery
Study Arms (1)
Patients with acute hemorrhagic cerebrovascular disease
Eligibility Criteria
The investigators plan to recruit patients aged 18-80 years with acute hemorrhagic cerebrovascular disease from a minimum of three tertiary Grade A general hospitals.
You may qualify if:
- Patients aged 18 to 80 years.
- Diagnosis confirmed by preoperative imaging (CT or MRI) of one of the following conditions:
- Intracranial aneurysm
- Arteriovenous malformation (AVM)
- Hemorrhagic moyamoya disease
- Cavernous malformation
- Spontaneous intracerebral hemorrhage
- Undergoing surgery within seven days of symptom onset.
You may not qualify if:
- Patients who decline to provide informed consent.
- Patients enrolled in conflicting clinical studies.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy chief of Department of Anesthesiology
Study Record Dates
First Submitted
May 9, 2025
First Posted
May 31, 2025
Study Start
July 6, 2025
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2028
Last Updated
May 31, 2025
Record last verified: 2025-04